Present and future scope of recombinant parathyroid hormone therapy in orthopaedics

Sain, Arnab; Bansal, Hemant; Pattabiraman, Kirubakaran; Vp, Sharma

doi:10.1016/j.jcot.2021.01.019

Cited by 7 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strategies to develop disease-modifying-treatments and newly established KOA medications have attracted much attention, which would reduce the costs and benefit patients. PTH (1–34) was used to treat OP, improve healing of the bone fracture widely [ 24 ], and emerge as a promising agent for KOA treatment. Therefore, PTH (1–34) might be a medication for KOA but the potential mechanism of its pharmacological effects remains to be explored.…”

Section: Discussionmentioning

confidence: 99%

Teriparatide ameliorates articular cartilage degradation and aberrant subchondral bone remodeling in DMM mice

Liu

Chen

et al. 2023

Journal of Orthopaedic Translation

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Teriparatide ameliorates articular cartilage degradation and aberrant subchondral bone remodeling in DMM mice

Liu

Chen

et al. 2023

Journal of Orthopaedic Translation

View full text Add to dashboard Cite

“… 7 On the contrary, anti-osteoporotic agents like teriparatide have been tried to enhance fracture healing due to its anabolic effect. 8 Following an acute fracture, the optimal timing of starting the osteoporosis medications especially for antiresorptive agents like bisphosphonate remains an important concern. The purpose of this review is to assess the current literature on the effect of timing of initiation of different osteoporosis medications following an incident fracture.…”

Section: Introductionmentioning

confidence: 99%

Timing of osteoporosis therapies following fracture: the current status

Palui

Durgia

Sahoo

et al. 2022

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

In most patients, osteoporosis is diagnosed only after the occurrence of the first fragility fracture. It is of utmost importance to start osteoporosis medications immediately in these patients to prevent future fractures and also to reduce associated mortality and morbidity. There remains a hesitancy over initiating osteoporotic medications, specifically for antiresorptive agents like bisphosphonates following an acute fracture due to concern over their effect on fracture healing. The purpose of this review is to study the effect of the timing of initiation of different osteoporosis medications on healing after an acute fracture. Most of the human studies, including randomized control trials (RCTs), did not find any significant negative effect on fracture healing with early use of bisphosphonate after an acute fracture. Anabolic agents like teriparatide have shown either neutral or beneficial effects on fracture healing and thus can be started very early following any osteoporotic fracture. Although human studies on the early use of other osteoporosis medications like denosumab or strontium ranelate are very sparse in the literature, none of these medications have shown any evidence of delay in fracture healing. To summarize, among the commonly used anti-osteoporosis agents, both bisphosphonates and teriparatide are safe to be initiated in the early acute post-fracture period. Moreover, teriparatide has shown some evidence in favor of reducing fracture healing time.

show abstract